Heidi Evidence Is Excellent. In the UK, It Won't Answer Mid-Consultation.

Heidi Evidence is the most strategically interesting clinical AI tool to land in 2026. It is free at the individual tier. It is citation-backed. It is partnered with NICE, BMJ Group, MIMS and HealthPathways — the four most credible UK clinical-content sources a tool in this space could pair with. We have read the output carefully. It is good.

In the UK, it will not answer during a live consultation.

Heidi documents Evidence as available to UK and EU users only outside live patient sessions. In-session evidence querying is disabled under current compliance settings. You can use it to read up between patients, to prepare, or to check a question after clinic — but not in the room, with the patient in front of you, at the moment the question arises.

That is a real limitation for a point-of-care tool. We think it matters, and it is worth being precise about.

What Heidi Evidence actually does

Heidi Evidence is a clinical decision support tool. You ask a clinical question — the kind of question you might have asked a colleague on the way to coffee — and it returns a synthesised answer with citations you can click through to.

The synthesis is grounded in named, recognisable UK sources. The NICE partnership means guidelines come from where they should come from. The BMJ Group content gives the answers a familiar editorial register. MIMS gives prescribing detail. HealthPathways adds local-pathway awareness for the regions where it is deployed.

Two things make Heidi Evidence stand out from earlier clinical AI tools.

The first is that the citations are honest. Click any reference and you land on the source — NICE guideline, BMJ article, MIMS entry — exactly as quoted. This is not always true of clinical AI tools, and it has been a real problem with some of the larger-funded US entries.

The second is that there is no advertising and no sponsored content. The product is free at the individual tier and the funding model does not depend on shaping which answers surface.

For UK clinicians, the catch is when you can use it. Out of session, it is available. In session, it is not.

What the in-session restriction actually looks like

The restriction is on context of use, not on access. A UK or EU clinician can hold a Heidi Evidence account. What they cannot do is run an evidence query during a live patient session.

In practice that splits Heidi Evidence's usefulness in two. The "I have ten minutes between patients and want to check the current line on a drug interaction" use case is supported. The "the patient is in front of me and I need an answer now" use case — the defining point-of-care moment — is the one the compliance configuration holds back in the UK and EU.

Heidi Scribe — the AI clinical scribe that drafts consultation notes — is a different story. Heidi Scribe is separately MHRA-cleared and remains available to UK clinicians, including NHS staff, in session. If you have been using Heidi Scribe, that is unaffected. The restriction is specific to Heidi Evidence's in-session use.

Why the restriction is in place

Heidi Health has not published a detailed rationale. The most likely explanation is regulatory.

Heidi Evidence generates AI-synthesised clinical recommendations from a clinical query. Used at the point of care, that is the kind of output that pushes a tool toward Software as a Medical Device territory under MHRA classification. The NICE, BMJ Group, MIMS and HealthPathways partnerships are content arrangements — they describe what the model is grounded in, not how the model is classified for live clinical use.

The UK regulatory framework for AI in healthcare is mid-flight. The Medical Devices (Amendment) Regulations consultation closes 19 June 2026. The International Reliance Framework is planned for Autumn 2026. The National Commission on AI in Healthcare report is due later in the year. Until these land, restricting an AI decision-support tool to out-of-session use is a cautious reading of an unsettled rulebook.

This sits in the same regulatory current that took OpenEvidence out of the UK and EU on 28 April 2026 and has kept ChatGPT for Clinicians US-first since 23 April. The difference is one of degree: those two stepped back entirely; Heidi Evidence stayed, with a limit on how it can be used.

The pattern UK clinicians should be aware of

In the space of six weeks, three clinical AI tools in the same category changed their UK footing:

• 23 April 2026: ChatGPT for Clinicians launches. UK and EEA excluded at the verification step.
• 28 April 2026: OpenEvidence withdraws from the UK and EU.
• 2026: Heidi Evidence operates in the UK and EU, but only outside live sessions — its in-session point-of-care use is restricted.

All three offered the same broad use case — point-of-care clinical Q&A grounded in cited sources. Two are now unavailable to UK clinicians; the third is available, but not in the one moment a point-of-care tool is most wanted.

We have written separately about the OpenEvidence withdrawal and the ChatGPT for Clinicians exclusion. Heidi Evidence is the third chapter in the same regulatory story.

What is striking is that Heidi Evidence — unlike the other two — is the one product that did everything right on the UK content side. NICE partnership. BMJ Group partnership. UK-relevant prescribing data. And it still pulls back from live point-of-care use. That is the regulatory environment talking, not the product.

What UK clinicians can use right now

For clinical Q&A at the point of care — in the room, in the moment: iatroX is the UK-based option. It holds MHRA registration as a Class I device, carries UKCA marking, and is built around UK guideline retrieval (NICE, CKS, SmPC) with calculators and Q-banks attached. It is not a perfect substitute for Heidi Evidence's model quality, but it is the most credible UK-regulatory-compliant in-session tool today.

For out-of-session evidence questions: Heidi Evidence itself is available and worth using — between patients, before clinic, after a consultation.

For AI clinical documentation: Heidi Scribe remains available and MHRA-cleared, in session included.

For staying current with the medical literature — knowing what was published in your specialty each week — that is a different job altogether. Q&A tools answer questions you have already thought to ask. They cannot tell you about the practice-changing trial that landed last Tuesday. That is the gap The Monday Clinical Brief is built to close.

We have written more on how Heidi Evidence and a weekly digest fit together — push and pull, current awareness and point-of-care.

A short note on Claude

Heidi Evidence is powered in part by Anthropic Claude. So is The Monday Clinical Brief — we use Claude to summarise the weekly journal output for each of our 31 specialties. We mention this only because it is worth knowing: the underlying model choice is the same. The product around the model is what differs. Heidi Evidence wraps the model in a query interface and clinical-source partnerships. MCB wraps the model in a weekly editorial cadence and a UK clinician's perspective.

What we offer

The Monday Clinical Brief sends one email every Monday morning. In that email are the most important peer-reviewed papers published in your specialty over the previous week — plain-language summaries, links to the originals, and the UK context (NICE, Royal College, NHS pathway) where it matters.

We cover 31 specialties. We are reader-paid at £20 a year. No advertising, no sponsored papers, no regulatory uncertainty — we are not a medical device and we do not claim to be one. We are a weekly reading habit you can log for CPD.

Subscribe to The Monday Clinical Brief — and know what was published last week before any of these AI tools could have told you about it.

The bottom line

Heidi Evidence is excellent. In the UK and EU, it works outside live sessions but not during them — so the defining point-of-care moment is the one it currently holds back from. This will probably ease once the UK regulatory framework for clinical AI lands, but the timeline is months, not weeks.

In the meantime: iatroX for in-session UK clinical Q&A, Heidi Evidence for out-of-session questions, Heidi Scribe for documentation if you want it, and MCB for keeping current with the literature itself. Each tool does one job well. Together they cover most of the ground.

We will update this post as Heidi Evidence's UK position changes. Evidence suggests any change will follow the Medical Devices (Amendment) Regulations consultation that closes in June 2026 — but until then, the in-session restriction holds.